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reamble
he medical profession should play a central role in evalu-
ing the evidence related to drugs, devices, and procedures
r the detection, management, and prevention of disease.
hen properly applied, expert analysis of available data on
e benefits and risks of these therapies and procedures can
prove the quality of care, optimize patient outcomes, and
vorably affect costs by focusing resources on the most
fective strategies. An organized and directed approach to a
orough review of evidence has resulted in the production of
inical practice guidelines that assist physicians in selecting
e best management strategy for an individual patient.
oreover, clinical practice guidelines can provide a founda-
on for other applications, such as performance measures,
propriate use criteria, and both quality improvement and
inical decision support tools.
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d the American Heart Association (AHA) have jointly
oduced guidelines in the area of cardiovascular disease
nce 1980. The ACCF/AHA Task Force on Practice Guide-
nes (Task Force), charged with developing, updating, and
vising practice guidelines for cardiovascular diseases and
ocedures, directs and oversees this effort. Writing commit-
es are charged with regularly reviewing and evaluating all
ailable evidence to develop balanced, patient-centric rec-
mendations for clinical practice.
Experts in the subject under consideration are selected by
e ACCF and AHA to examine subject-specific data and
rite guidelines in partnership with representatives from
her medical organizations and specialty groups. Writing
mmittees are asked to perform a literature review; weigh
e strength of evidence for or against particular tests,
eatments, or procedures; and include estimates of expected
tcomes where such data exist. Patient-specific modifiers,
morbidities, and issues of patient preference that may
fluence the choice of tests or therapies are considered.
hen available, information from studies on cost is consid-
ed, but data on efficacy and outcomes constitute the primary
sis for the recommendations contained herein.
In analyzing the data and developing recommendations and
pporting text, the writing committee uses evidence-based
ethodologies developed by the Task Force (1). The Class of
ecommendation (COR) is an estimate of the size of the
eatment effect considering risks versus benefits in addition to
idence and/or agreement that a given treatment or procedure is
is not useful/effective or in some situations may cause harm.
he Level of Evidence (LOE) is an estimate of the certainty or
ecision of the treatment effect. The writing committee reviews
d ranks evidence supporting each recommendation with the
eight of evidence ranked as LOE A, B, or C according to
ecific definitions that are included in Table 1. Studies are
entified as observational, retrospective, prospective, or ran-
mized where appropriate. For certain conditions for which
adequate data are available, recommendations are based on
pert consensus and clinical experience and are ranked as LOE C.
hen recommendations at LOE C are supported by historical
inical data, appropriate references (including clinical reviews) are
ted if available. For issues for which sparse data are available, a
rvey of current practice among the clinician members of the
riting committee is the basis for LOE C recommendations and no
ferences are cited. The schema for COR and LOE is summarized
Table 1, which also provides suggested phrases for writing
commendations within each COR.
A new addition to this methodology is separation of the
lass III recommendations to delineate whether the recommen-
tion is determined to be of “no benefit” or is associated with
arm” to the patient. In addition, in view of the increasing
mber of comparative effectiveness studies, comparator verbs
d suggested phrases for writing recommendations for the
mparative effectiveness of one treatment or strategy versus
other are included for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the spectrum
cardiovascular diseases, the Task Force has designated the
rm guideline-directed medical therapy (GDMT) to repre-
nt optimal medical therapy as defined by ACCF/AHA guideline- frcommended therapies (primarily Class I). This new term, GDMT,
ill be used throughout subsequent guidelines.
Because the ACCF/AHA practice guidelines address patient
pulations (and healthcare providers) residing in North Amer-
a, drugs that are not currently available in North America are
scussed in the text without a specific COR. For studies
rformed in large numbers of subjects outside North America,
ch writing committee reviews the potential influence of different
actice patterns and patient populations on the treatment effect and
levance to the ACCF/AHA target population to determine
hether the findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describing a
nge of generally acceptable approaches to the diagnosis,
anagement, and prevention of specific diseases or conditions.
he guidelines attempt to define practices that meet the needs of
ost patients in most circumstances. The ultimate judgment
garding care of a particular patient must be made by the
althcare provider and patient in light of all the circumstances
esented by that patient. As a result, situations may arise for
hich deviations from these guidelines may be appropriate.
linical decision making should involve consideration of the
ality and availability of expertise in the area where care is
ovided. When these guidelines are used as the basis for regulatory
payer decisions, the goal should be improvement in quality of
re. The Task Force recognizes that situations arise in which
ditional data are needed to inform patient care more effectively;
ese areas are identified within each respective guideline when
propriate.
Prescribed courses of treatment in accordance with these
commendations are effective only if followed. Because lack
patient understanding and adherence may adversely affect
tcomes, physicians and other healthcare providers should
ake every effort to engage the patient’s active participation
prescribed medical regimens and lifestyles. In addition,
tients should be informed of the risks, benefits, and alterna-
es to a particular treatment and should be involved in shared
cision making whenever feasible, particularly for COR IIa and
b, for which the benefit-to-risk ratio may be lower.
The Task Force makes every effort to avoid actual, poten-
al, or perceived conflicts of interest that may arise as a result
relationships with industry and other entities (RWI) among
e members of the writing committee. All writing committee
embers and peer reviewers of the guideline are required to
sclose all current healthcare related relationships, including
ose existing 12 months before initiation of the writing
fort. In December 2009, the ACCF and AHA implemented
new RWI policy that requires the writing committee chair
us a minimum of 50% of the writing committee to have no
levant RWI. (Appendix 1 includes the ACCF/AHA defini-
on of relevance.) These statements are reviewed by the Task
orce and all members during each conference call and/or
eeting of the writing committee, and members provide
dates as changes occur. All guideline recommendations
quire a confidential vote by the writing committee and must
approved by a consensus of the voting members. Members
ay not draft or vote on any text or recommendations
rtaining to their RWI. Members who recused themselvesom voting are indicated in the list of writing committee
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uthors’ and peer reviewers’ RWI pertinent to this guideline
e disclosed in Appendixes 1 and 2, respectively. In addition,
ensure complete transparency, writing committee mem-
rs’ comprehensive disclosure information—including RWI
t pertinent to this document—is available as an online
pplement. Comprehensive disclosure information for the
ask Force is also available online at http://www.
rdiosource.org/ACC/About-ACC/Who-We-Are/Leadership/
uidelines-and-Documents-Task-Forces.aspx. The work of writ-
g committees is supported exclusively by the ACCF and AHA
ithout commercial support. Writing committee members volun-
ered their time for this activity.
In an effort to maintain relevance at the point of care for
ble 1. Applying Classification of Recommendation and Level o
A recommendation with Level of Evidence B or C does not imply that the recomme
emselves to clinical trials. Although randomized trials are unavailable, there may be a
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evi
rect comparisons of the treatments or strategies being evaluated.acticing physicians, the Task Force continues to oversee an wgoing process improvement initiative. As a result, in
sponse to pilot projects, several changes to these guidelines
ill be apparent, including limited narrative text, a focus on
mmary and evidence tables (with references linked to
stracts in PubMed), and more liberal use of summary
commendation tables (with references that support LOE) to
rve as a quick reference.
In April 2011, the Institute of Medicine released 2
ports: Finding What Works in Health Care: Standards
r Systematic Reviews and Clinical Practice Guidelines
e Can Trust (2,3). It is noteworthy that the IOM cited
CCF/AHA practice guidelines as being compliant with
any of the proposed standards. A thorough review of
ese reports and of our current methodology is under way,
nce
s weak. Many important clinical questions addressed in the guidelines do not lend
r clinical consensus that a particular test or therapy is useful or effective.
rent subpopulations, such as sex, age, history of diabetes, history of prior
and B only), studies that support the use of comparator verbs should involvef Evide
ndation i
very clea
in diffe
dence Aith further enhancements anticipated.
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rrent until they are superseded by a focused update or the
ll-text guideline is revised. The reader is encouraged to
nsult the full-text guideline (4) for additional guidance and
tails about the care of the patient with ST-elevation
yocardial infarction (STEMI), because the Executive Sum-
ary contains only the recommendations. Guidelines are
ficial policy of both the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
he recommendations listed in this document are, whenever
ssible, evidence based. The current document constitutes a
ll revision and includes an extensive evidence review which
as conducted through November 2010, with additional
lected references added through August 2012. Searches
ere limited to studies conducted in human subjects and
views and other evidence pertaining to human subjects; all
ere published in English. Key search words included but
ere not limited to: acute coronary syndromes, percutaneous
ronary intervention, coronary artery bypass graft, myocar-
al infarction, ST-elevation myocardial infarction, coronary
ent, revascularization, anticoagulant therapy, antiplatelet
erapy, antithrombotic therapy, glycoprotein IIb/IIIa inhib-
or therapy, pharmacotherapy, proton-pump inhibitor, im-
antable cardioverter-defibrillator therapy, cardiogenic
ock, fibrinolytic therapy, thrombolytic therapy, nitrates,
echanical complications, arrhythmia, angina, chronic sta-
e angina, diabetes, chronic kidney disease, mortality, mor-
dity, elderly, ethics, and contrast nephropathy. Additional
arches cross-referenced these topics with the following
btopics: percutaneous coronary intervention, coronary ar-
ry bypass graft, cardiac rehabilitation, and secondary
evention. Additionally, the committee reviewed documents
lated to the subject matter previously published by the
CCF and AHA. References selected and published in this
cument are representative and not all inclusive.
The focus of this guideline is the management of patients with
TEMI. Updates to the 2004 STEMI guideline were published
2007 and 2009 (5–7). Particular emphasis is placed on
vances in reperfusion therapy, organization of regional sys-
ms of care, transfer algorithms, evidence-based antithrombotic
d medical therapies, and secondary prevention strategies to
timize patient-centered care. By design, the document is
rrower in scope than the 2004 STEMI Guideline, in an attempt
provide a more focused tool for practitioners. References
lated to management guidelines are provided whenever appro-
iate, including those pertaining to percutaneous coronary
tervention (PCI), coronary artery bypass graft (CABG), heart
ilure (HF), cardiac devices, and secondary prevention.
.2. Organization of the Writing Committee
he writing committee was composed of experts representing
rdiovascular medicine, interventional cardiology, electro-
ysiology, HF, cardiac surgery, emergency medicine, inter- effl medicine, cardiac rehabilitation, nursing, and pharmacy.
he American College of Physicians, American College of
mergency Physicians, and Society for Cardiovascular An-
ography and Interventions assigned official representatives.
.3. Document Review and Approval
his document was reviewed by 2 outside reviewers each
minated by the ACCF and the AHA, as well as 2 reviewers
ch from the American College of Emergency Physicians
d Society for Cardiovascular Angiography and Interven-
ons and 22 individual content reviewers (including members
om the ACCF Interventional Scientific Council and ACCF
urgeons’ Scientific Council). All reviewer RWI information
as distributed to the writing committee and is published in
is document (Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF and the AHA and was endorsed
the American College of Emergency Physicians and
ociety for Cardiovascular Angiography and Interventions.
. Onset of Myocardial Infarction:
ecommendations
.1. Regional Systems of STEMI Care,
eperfusion Therapy, and
ime-to-Treatment Goals
ee Figure 1.
ASS I
All communities should create and maintain a regional system
of STEMI care that includes assessment and continuous qual-
ity improvement of emergency medical services and hospital-
based activities. Performance can be facilitated by participat-
ing in programs such as Mission: Lifeline and the Door-to-
Balloon Alliance (8–11). (Level of Evidence: B)
Performance of a 12-lead electrocardiogram (ECG) by emer-
gency medical services personnel at the site of first medical
contact (FMC) is recommended in patients with symptoms
consistent with STEMI (11–15). (Level of Evidence: B)
Reperfusion therapy should be administered to all eligible
patients with STEMI with symptom onset within the prior 12
hours (16,17). (Level of Evidence: A)
Primary PCI is the recommended method of reperfusion when it
can be performed in a timely fashion by experienced operators
(17–19). (Level of Evidence: A)
Emergency medical services transport directly to a PCI-
capable hospital for primary PCI is the recommended triage
strategy for patients with STEMI, with an ideal FMC-to-device
time system goal of 90 minutes or less* (11,14,15). (Level of
Evidence: B)
Immediate transfer to a PCI-capable hospital for primary PCI is
the recommended triage strategy for patients with STEMI who
initially arrive at or are transported to a non–PCI-capable
hospital, with an FMC-to-device time system goal of 120
minutes or less* (18–21). (Level of Evidence: B)
In the absence of contraindications, fibrinolytic therapy should
be administered to patients with STEMI at non–PCI-capable
he proposed time windows are system goals. For any individual patient, every
ort should be made to provide reperfusion therapy as rapidly as possible.
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capable hospital exceeds 120 minutes because of unavoidable
delays (16,22,23). (Level of Evidence: B)
When fibrinolytic therapy is indicated or chosen as the primary
reperfusion strategy, it should be administered within 30
minutes of hospital arrival* (24–28). (Level of Evidence: B)
ASS IIa
Reperfusion therapy is reasonable for patients with STEMI and
symptom onset within the prior 12 to 24 hours who have
clinical and/or ECG evidence of ongoing ischemia. Primary PCI
is the preferred strategy in this population (16,29,30). (Level
of Evidence: B)
.2. Evaluation and Management of Patients
ith STEMI and Out-of-Hospital Cardiac Arrest
ASS I
Therapeutic hypothermia should be started as soon as possible in
comatose patients with STEMI and out-of-hospital cardiac arrest
caused by ventricular fibrillation or pulseless ventricular tachycar-
dia, including patients who undergo primary PCI (31–33). (Level
of Evidence: B)
Immediate angiography and PCI when indicated should be per-
formed in resuscitated out-of-hospital cardiac arrest patients
gure 1. Reperfusion therapy for patients with STEMI. The bold a
ctated by an anatomically appropriate culprit stenosis. Patients w
pable hospital should be transferred for cardiac catheterization and
I onset (Class I, LOE: B). †Angiography and revascularization should
rinolytic therapy. CABG indicates coronary artery bypass graft; DID
nce; MI, myocardial infarction; PCI, percutaneous coronary intervenwhose initial ECG shows STEMI (34–49). (Level of Evidence: B) ne. Reperfusion at a PCI-Capable Hospital:
ecommendations
.1. Primary PCI in STEMI
ee Table 2 for a summary of recommendations from this
ction.
and boxes are the preferred strategies. Performance of PCI is
iogenic shock or severe heart failure initially seen at a non–PCI-
ularization as soon as possible, irrespective of time delay from
e performed within the first 2 to 3 hours after administration of
r-in–door-out; FMC, first medical contact; LOE, Level of Evi-
nd STEMI, ST-elevation myocardial infarction.
ble 2. Primary PCI in STEMI
COR LOE References
hemic symptoms 12 h I A (17,50,51)
hemic symptoms 12 h and
ntraindications to fibrinolytic therapy
espective of time delay from FMC
I B (52,53)
rdiogenic shock or acute severe HF
espective of time delay from MI onset
I B (54–57)
idence of ongoing ischemia 12 to 24 h
ter symptom onset
IIa B (29,30)
I of a noninfarct artery at the time of
imary PCI in patients without
modynamic compromise
III: Harm B (58–60)
COR indicates Class of Recommendation; FMC, first medical contact; HF,
art failure; LOE, Level of Evidence; MI, myocardial infarction; PCI, percuta-rrows
ith card
revasc
not b
O, dooous coronary intervention; and STEMI, ST-elevation myocardial infarction.
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Primary PCI should be performed in patients with STEMI and isch-
emic symptoms of less than 12 hours’ duration (17,50,51). (Level of
Evidence: A)
Primary PCI should be performed in patients with STEMI and
ischemic symptoms of less than 12 hours’ duration who have
contraindications to fibrinolytic therapy, irrespective of the
time delay from FMC (52,53). (Level of Evidence: B)
Primary PCI should be performed in patients with STEMI and
cardiogenic shock or acute severe HF, irrespective of time
delay from myocardial infarction (MI) onset (Section 8.1)
(54–57). (Level of Evidence: B)
ASS IIa
Primary PCI is reasonable in patients with STEMI if there is
clinical and/or ECG evidence of ongoing ischemia between 12 and
24 hours after symptom onset (29,30). (Level of Evidence: B)
ASS III: HARM
PCI should not be performed in a noninfarct artery at the time
of primary PCI in patients with STEMI who are hemodynami-
cally stable (58–60). (Level of Evidence: B)
.2. Aspiration Thrombectomy
ASS IIa
Manual aspiration thrombectomy is reasonable for patients
undergoing primary PCI (61–64). (Level of Evidence: B)
.3. Use of Stents in Patients With STEMI
ASS I
Placement of a stent (bare-metal stent or drug-eluting stent) is
useful in primary PCI for patients with STEMI (65,66). (Level of
Evidence: A)
Bare-metal stents† should be used in patients with high bleed-
ing risk, inability to comply with 1 year of dual antiplatelet
therapy (DAPT), or anticipated invasive or surgical procedures
in the next year. (Level of Evidence: C)
ASS III: HARM
Drug-eluting stents should not be used in primary PCI for
patients with STEMI who are unable to tolerate or comply with
a prolonged course of DAPT because of the increased risk of
stent thrombosis with premature discontinuation of one or both
agents (67–73). (Level of Evidence: B)
.4. Antiplatelet Therapy to Support Primary
CI for STEMI
ee Table 3 for a summary of recommendations from this
ction.
ASS I
Aspirin 162 to 325 mg should be given before primary PCI
(74–76). (Level of Evidence: B)
After PCI, aspirin should be continued indefinitely (77,78,80).
(Level of Evidence: A)
A loading dose of a P2Y12 receptor inhibitor should be given as
early as possible or at time of primary PCI to patients with
STEMI. Options includealloon angioplasty without stent placement may be used in selected patients. daa. Clopidogrel 600 mg (76,81,82) (Level of Evidence: B); or
b. Prasugrel 60 mg (83) (Level of Evidence: B); or
c. Ticagrelor 180 mg (84). (Level of Evidence: B)
P2Y12 inhibitor therapy should be given for 1 year to patients
with STEMI who receive a stent (bare-metal or drug-eluting)
during primary PCI using the following maintenance doses:
a. Clopidogrel 75 mg daily (83,85) (Level of Evidence: B); or
b. Prasugrel 10 mg daily (85) (Level of Evidence: B); or
c. Ticagrelor 90 mg twice a day (84).‡ (Level of Evidence: B)
ASS IIa
It is reasonable to use 81 mg of aspirin per day in preference to
higher maintenance doses after primary PCI (76,77,86,87).
(Level of Evidence: B)
It is reasonable to start treatment with an intravenous
glycoprotein (GP) IIb/IIIa receptor antagonist such as ab-
ciximab (88–90) (Level of Evidence: A), high-bolus-dose
tirofiban (91,92) (Level of Evidence: B), or double-bolus
eptifibatide (93) (Level of Evidence: B) at the time of primary
PCI (with or without stenting or clopidogrel pretreatment) in
selected patients with STEMI who are receiving unfraction-
ated heparin (UFH).
ASS IIb
It may be reasonable to administer intravenous GP IIb/IIIa
receptor antagonist in the precatheterization laboratory set-
ting (e.g., ambulance, emergency department) to patients with
STEMI for whom primary PCI is intended (91,94–101). (Level
of Evidence: B)
It may be reasonable to administer intracoronary abciximab to
patients with STEMI undergoing primary PCI (64,102–108).
(Level of Evidence: B)
Continuation of a P2Y12 inhibitor beyond 1 year may be
considered in patients undergoing drug-eluting stent place-
ment. (Level of Evidence: C)
ASS III: HARM
Prasugrel should not be administered to patients with a history
of prior stroke or transient ischemic attack (83). (Level of
Evidence: B)
.5. Anticoagulant Therapy to Support
rimary PCI
ASS I
For patients with STEMI undergoing primary PCI, the following
supportive anticoagulant regimens are recommended:
a. UFH, with additional boluses administered as needed to
maintain therapeutic activated clotting time levels, taking
into account whether a GP IIb/IIIa receptor antagonist has
been administered (Level of Evidence: C); or
b. Bivalirudin with or without prior treatment with UFH (109).
(Level of Evidence: B)
ASS IIa
In patients with STEMI undergoing PCI who are at high risk of
bleeding, it is reasonable to use bivalirudin monotherapy in
he recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg
ily.
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2013 ACCF/AHA STEMI Guideline Executive Summary January 29, 2013:485–510ble 3. Adjunctive Antithrombotic Therapy to Support Reperfusion With Primary PCI
COR LOE References
tiplatelet therapy
pirin
162- to 325-mg load before procedure I B (74–76)
81- to 325-mg daily maintenance dose (indefinite)* I A (77,78,80)
81 mg daily is the preferred maintenance dose* IIa B (76,77,86,87)
Y12 inhibitors
Loading doses
Clopidogrel: 600 mg as early as possible or at time of PCI I B (76,81,82)
Prasugrel: 60 mg as early as possible or at time of PCI I B (83)
Ticagrelor: 180 mg as early as possible or at time of PCI I B (84)
Maintenance doses and duration of therapy
S placed: Continue therapy for 1 y with:
Clopidogrel: 75 mg daily I B (83,85)
Prasugrel: 10 mg daily I B (85)
Ticagrelor: 90 mg twice a day* I B (84)
S† placed: Continue therapy for 1 y with:
Clopidogrel: 75 mg daily I B (83,85)
Prasugrel: 10 mg daily I B (85)
Ticagrelor: 90 mg twice a day* I B (84)
S placed:
Clopidogrel, prasugrel, or ticagrelor* continued beyond 1 y IIb C N/A
Patients with STEMI with prior stroke or TIA: prasugrel III: Harm B (83)
GP IIb/IIIa receptor antagonists in conjunction with UFH or bivalirudin in selected patients
Abciximab: 0.25-mg/kg IV bolus, then 0.125 mcg/kg/min (maximum 10 mcg/min) IIa A (88–90)
Tirofiban: (high-bolus dose): 25-mcg/kg IV bolus, then 0.15 mcg/kg/min
● In patients with CrCl 30 mL/min, reduce infusion by 50%
IIa B (91,92)
Eptifibatide: (double bolus): 180-mcg/kg IV bolus, then 2 mcg/kg/min; a second 180-mcg/kg bolus is
administered 10 min after the first bolus
● In patients with CrCl 50 mL/min, reduce infusion by 50%
● Avoid in patients on hemodialysis
IIa B (93)
Pre–catheterization laboratory administration of intravenous GP IIb/IIIa receptor antagonist IIb B (91,94–101)
Intracoronary abciximab 0.25-mg/kg bolus IIb B (64,102–108)
ticoagulant therapy
UFH: I C N/A
● With GP IIb/IIIa receptor antagonist planned: 50- to 70-U/kg IV bolus to achieve therapeutic ACT‡
● With no GP IIb/IIIa receptor antagonist planned: 70- to 100-U/kg bolus to achieve therapeutic ACT§ I C N/A
Bivalirudin: 0.75-mg/kg IV bolus, then 1.75-mg/kg/h infusion with or without prior treatment with
UFH. An additional bolus of 0.3 mg/kg can be given if needed.
● Reduce infusion to 1 mg/kg/h with estimated CrCl 30 mL/min
I B (109)
● Preferred over UFH with GP IIb/IIIa receptor antagonist in patients at high risk of bleeding IIa B (109)
Fondaparinux: Not recommended as sole anticoagulant for primary PCI III: Harm B (110)
ACT indicates activated clotting time; BMS, bare-metal stent; CrCl, creatinine clearance; COR, Class of Recommendation; DES, drug-eluting stent; GP, glycoprotein;
, intravenous; LOE, Level of Evidence; N/A, not available; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic
tack; and UFH, unfractionated heparin.
*The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily.
†Balloon angioplasty without stent placement may be used in selected patients. It might be reasonable to provide P2Y12 inhibitor therapy to patients with STEMI
dergoing balloon angioplasty alone according to the recommendations listed for BMS. (LOE: C)
‡The recommended ACT with planned GP IIb/IIIa receptor antagonist treatment is 200 to 250 s.
§The recommended ACT with no planned GP IIb/IIIa receptor antagonist treatment is 250 to 300 s (HemoTec device) or 300 to 350 s (Hemochron device).
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receptor antagonist (109). (Level of Evidence: B)
ASS III: HARM
Fondaparinux should not be used as the sole anticoagulant to
support primary PCI because of the risk of catheter thrombosis
(110). (Level of Evidence: B)
. Reperfusion at a Non–PCI-Capable
ospital: Recommendations
.1. Fibrinolytic Therapy When There Is an
nticipated Delay to Performing Primary PCI
ithin 120 Minutes of FMC
ee Table 4 for a summary of recommendations from this
ction.
ASS I
In the absence of contraindications, fibrinolytic therapy should
be given to patients with STEMI and onset of ischemic symp-
toms within the previous 12 hours when it is anticipated that
primary PCI cannot be performed within 120 minutes of FMC
(16,111–116). (Level of Evidence: A)
ASS IIa
In the absence of contraindications and when PCI is not
available, fibrinolytic therapy is reasonable for patients with
STEMI if there is clinical and/or electrocardiographic evidence
of ongoing ischemia within 12 to 24 hours of symptom onset
and a large area of myocardium at risk or hemodynamic
instability. (Level of Evidence: C)
ASS III: HARM
Fibrinolytic therapy should not be administered to patients with
ST depression except when a true posterior (inferobasal) MI is
suspected or when associated with ST elevation in lead aVR
(16,117–120). (Level of Evidence: B)
.2. Adjunctive Antithrombotic Therapy With
ibrinolysis
ee Table 5 for a summary of recommendations from this
ction.
ble 4. Indications for Fibrinolytic Therapy When There Is a
120-Minute Delay From FMC to Primary PCI (Figure 1)
COR LOE References
hemic symptoms 12 h I A (16,111–116)
idence of ongoing ischemia 12 to
h after symptom onset, and a
rge area of myocardium at risk or
modynamic instability
IIa C N/A
depression except if true posterior
ferobasal) MI suspected or when
sociated with ST-elevation in lead
R
III: Harm B (16,117–120)
COR indicates Class of Recommendation; FMC, first medical contact; LOE,
vel of Evidence; MI, myocardial infarction; N/A, not available; and PCI,
rcutaneous coronary intervention..2.1. Adjunctive Antiplatelet Therapy With
ibrinolysis
ASS I
Aspirin (162- to 325-mg loading dose) and clopidogrel (300-mg
loading dose for patients <75 years of age, 75-mg dose for
patients >75 years of age) should be administered to patients
with STEMI who receive fibrinolytic therapy (113,121,122).
(Level of Evidence: A)
Aspirin should be continued indefinitely (113,121,122) (Level
of Evidence: A) and clopidogrel (75 mg daily) should be
continued for at least 14 days (121,122) (Level of Evidence: A)
and up to 1 year (Level of Evidence: C) in patients with STEMI
who receive fibrinolytic therapy.
ASS IIa
It is reasonable to use aspirin 81 mg per day in preference to higher
maintenance doses after fibrinolytic therapy (77,80,86,87). (Level of
Evidence: B)
.2.2. Adjunctive Anticoagulant Therapy With
ibrinolysis
ASS I
Patients with STEMI undergoing reperfusion with fibrinolytic
therapy should receive anticoagulant therapy for a minimum
of 48 hours, and preferably for the duration of the index
hospitalization, up to 8 days or until revascularization if
performed (123,124). (Level of Evidence: A) Recommended
regimens include
a. UFH administered as a weight-adjusted intravenous bolus
and infusion to obtain an activated partial thromboplastin
time of 1.5 to 2.0 times control, for 48 hours or until
revascularization (Level of Evidence: C);
b. Enoxaparin administered according to age, weight, and
creatinine clearance, given as an intravenous bolus,
followed in 15 minutes by subcutaneous injection for the
duration of the index hospitalization, up to 8 days or until
revascularization (124–127) (Level of Evidence: A); or
c. Fondaparinux administered with initial intravenous dose,
followed in 24 hours by daily subcutaneous injections if the
estimated creatinine clearance is greater than 30 mL/min,
for the duration of the index hospitalization, up to 8 days or
until revascularization (110). (Level of Evidence: B)
.3. Transfer to a PCI-Capable Hospital After
ibrinolytic Therapy
.3.1. Transfer of Patients With STEMI to a PCI-
apable Hospital for Coronary Angiography After
ibrinolytic Therapy
ee Table 6 for a summary of recommendations from this
ction; Online Data Supplement 4 for additional data on
rly catheterization and rescue PCI for fibrinolytic failure in
e stent era; and Online Data Supplement 5 for additional data on
rly catheterization and PCI after fibrinolysis in the stent era.
ASS I
Immediate transfer to a PCI-capable hospital for coronary angiogra-
phy is recommended for suitable patients with STEMI who develop
cardiogenic shock or acute severe HF, irrespective of the time delay
from MI onset (128). (Level of Evidence: B)
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Urgent transfer to a PCI-capable hospital for coronary angiog-
raphy is reasonable for patients with STEMI who demonstrate
evidence of failed reperfusion or reocclusion after fibrinolytic
therapy (129–132). (Level of Evidence: B)
ble 5. Adjunctive Antithrombotic Therapy to Support Reperfus
tiplatelet Therapy
pirin
162- to 325-mg loading dose
81- to 325-mg daily maintenance dose (indefinite)
81 mg daily is the preferred maintenance dose
Y12 receptor inhibitors
Clopidogrel:
● Age 75 y: 300-mg loading dose
● Followed by 75 mg daily for at least 14 d and up to 1 y in absence of
● Age 75 y: no loading dose, give 75 mg
● Followed by 75 mg daily for at least 14 d and up to 1 y in absence of
ticoagulant Therapy
UFH:
● Weight-based IV bolus and infusion adjusted to obtain aPTT of 1.5 to 2.0 times con
48 h or until revascularization. IV bolus of 60 U/kg (maximum 4000 U) followed by
infusion of 12 U/kg/h (maximum 1000 U) initially, adjusted to maintain aPTT at 1.5
times control (approximately 50 to 70 s) for 48 h or until revascularization.
Enoxaparin:
● If age 75 y: 30-mg IV bolus, followed in 15 min by 1 mg/kg subcutaneo
every 12 h (maximum 100 mg for the first 2 doses)
● If age 75 y: no bolus, 0.75 mg/kg subcutaneously every 12 h (maximum
for the first 2 doses)
● Regardless of age, if CrCl 30 mL/min: 1 mg/kg subcutaneously every 24
● Duration: For the index hospitalization, up to 8 d or until revascularization
Fondaparinux:
● Initial dose 2.5 mg IV, then 2.5 mg subcutaneously daily starting the follow
for the index hospitalization up to 8 d or until revascularization
● Contraindicated if CrCl 30 mL/min
aPTT indicates activated partial thromboplastin time; COR, Class of Recomme
ailable; and UFH, unfractionated heparin.
ble 6. Indications for Transfer for Angiography After
brinolytic Therapy
COR LOE References
mediate transfer for cardiogenic shock or
vere acute HF irrespective of time delay
m MI onset
I B (128)
gent transfer for failed reperfusion or
occlusion
IIa B (129–132)
part of an invasive strategy in stable*
tients with PCI between 3 and 24 h after
ccessful fibrinolysis
IIa B (133–138)
COR indicates Class of Recommendation; HF, heart failure; LOE, Level of
idence; MI, myocardial infarction; N/A, not available; and PCI, percutaneous
ronary intervention.
*Although individual circumstances will vary, clinical stability is defined by
e absence of low output, hypotension, persistent tachycardia, apparent
ock, high-grade ventricular or symptomatic supraventricular tachyarrhyth-ouias, and spontaneous recurrent ischemia.Transfer to a PCI-capable hospital for coronary angiography is
reasonable for patients with STEMI who have received fibrino-
lytic therapy even when hemodynamically stable§ and with
clinical evidence of successful reperfusion. Angiography can be
performed as soon as logistically feasible at the receiving
hospital, and ideally within 24 hours, but should not be
performed within the first 2 to 3 hours after administration of
fibrinolytic therapy (133–138). (Level of Evidence: B)
. Delayed Invasive Management:
ecommendations
.1. Coronary Angiography in Patients Who
itially Were Managed With Fibrinolytic
herapy or Who Did Not Receive Reperfusion
ee Table 7 for a summary of recommendations from this
ction.
lthough individual circumstances will vary, clinical stability is defined by the
sence of low output, hypotension, persistent tachycardia, apparent shock, high-
ade ventricular or symptomatic supraventricular tachyarrhythmias, and spontane-
th Fibrinolytic Therapy
COR LOE References
I A (113,121,122)
I A (113,121,122)
IIa B (77,80,86,87)
I A (121,122)
I A (14 d) (121,122)
C (up to 1 y) N/A
I A (121,122)
I A (14 d) (121,122)
C (up to 1 y) N/A
I C N/A
I A (124–127)
I B (110)
,
CrCl, creatinine clearance; IV, intravenous; LOE, Level of Evidence; N/A, notion Wi
bleeding
bleeding
trol for
an
to 2.0
usly
75 mg
h
ing day
ndation;s recurrent ischemia.
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Cardiac catheterization and coronary angiography with in-
tent to perform revascularization should be performed after
STEMI in patients with any of the following:
a. Cardiogenic shock or acute severe HF that develops after initial
presentation (57,128,139,140) (Level of Evidence: B);
b. Intermediate- or high-risk findings on predischarge nonin-
vasive ischemia testing (141,142) (Level of Evidence:
B); or
c. Myocardial ischemia that is spontaneous or provoked by
minimal exertion during hospitalization. (Level of Evi-
dence: C)
ASS IIa
Coronary angiography with intent to perform revasculariza-
tion is reasonable for patients with evidence of failed
reperfusion or reocclusion after fibrinolytic therapy. Angiog-
raphy can be performed as soon as logistically feasible
(129–132). (Level of Evidence: B)
Coronary angiography is reasonable before hospital discharge in
stable§ patients with STEMI after successful fibrinolytic therapy.
Angiography can be performed as soon as logistically feasible,
and ideally within 24 hours, but should not be performed within
the first 2 to 3 hours after administration of fibrinolytic therapy
(133–138,143). (Level of Evidence: B)
.2. PCI of an Infarct Artery in Patients Who
itially Were Managed With Fibrinolysis or
ho Did Not Receive Reperfusion Therapy
ee Table 8 for a summary of recommendations from this
ction.
ASS I
PCI of an anatomically significant stenosis in the infarct artery
should be performed in patients with suitable anatomy and any
of the following:
a. Cardiogenic shock or acute severe HF (128) (Level of
Evidence: B);
ble 7. Indications for Coronary Angiography in Patients
ho Were Managed With Fibrinolytic Therapy or Who Did Not
eceive Reperfusion Therapy
COR LOE References
rdiogenic shock or acute severe HF that
velops after initial presentation
I B (57,128,
139,140)
termediate- or high-risk findings on
edischarge noninvasive ischemia testing
I B (141,142)
ontaneous or easily provoked myocardial
hemia
I C N/A
iled reperfusion or reocclusion after fibrinolytic
erapy
IIa B (129–132)
able* patients after successful fibrinolysis,
fore discharge and ideally between 3 and 24 h
IIa B (133–138,143)
COR indicates Class of Recommendation; HF, heart failure; LOE, Level of
idence; N/A, not available.
*Although individual circumstances will vary, clinical stability is defined by
e absence of low output, hypotension, persistent tachycardia, apparent
ock, high-grade ventricular or symptomatic supraventricular tachyarrhyth-ouias, and spontaneous recurrent ischemia.b. Intermediate- or high-risk findings on predischarge noninvasive
ischemia testing (141,142) (Level of Evidence: C); or
c. Myocardial ischemia that is spontaneous or provoked by
minimal exertion during hospitalization. (Level of Evi-
dence: C)
ASS IIa
Delayed PCI is reasonable in patients with STEMI and evidence
of failed reperfusion or reocclusion after fibrinolytic therapy.
PCI can be performed as soon as logistically feasible at the
receiving hospital (130,130a–130c) (Level of Evidence: B)
Delayed PCI of a significant stenosis in a patent infarct artery
is reasonable in stable§ patients with STEMI after fibrinolytic
therapy. PCI can be performed as soon as logistically feasible at
the receiving hospital, and ideally within 24 hours, but should not
be performed within the first 2 to 3 hours after administration of
fibrinolytic therapy (133–138). (Level of Evidence: B)
ASS IIb
Delayed PCI of a significant stenosis in a patent infarct artery
greater than 24 hours after STEMI may be considered as part
of an invasive strategy in stable§ patients (55,141–148).
(Level of Evidence: B)
ASS III: NO BENEFIT
Delayed PCI of a totally occluded infarct artery greater than 24
hours after STEMI should not be performed in asymptomatic
patients with 1- or 2-vessel disease if they are hemodynami-
cally and electrically stable and do not have evidence of severe
ischemia (55,146). (Level of Evidence: B)
lthough individual circumstances will vary, clinical stability is defined by the
sence of low output, hypotension, persistent tachycardia, apparent shock, high-
ade ventricular or symptomatic supraventricular tachyarrhythmias, and spontane-
ble 8. Indications for PCI of an Infarct Artery in Patients
ho Were Managed With Fibrinolytic Therapy or Who Did Not
eceive Reperfusion Therapy
COR LOE References
rdiogenic shock or acute severe HF I B (128)
termediate- or high-risk findings on
edischarge noninvasive ischemia testing
I C (141,142)
ontaneous or easily provoked myocardial
hemia
I C N/A
tients with evidence of failed reperfusion
reocclusion after fibrinolytic therapy (as
on as possible)
IIa B (130,130a–130c)
able* patients after successful fibrinolysis,
ally between 3 and 24 h
IIa B (133–138)
able* patients 24 h after successful
rinolysis
IIb B (55,141–148)
layed PCI of a totally occluded infarct
tery 24 h after STEMI in stable patients
III: No
Benefit
B (55,146)
COR indicates Class of Recommendation; HF, heart failure; LOE, Level of
idence; N/A, not available; PCI, percutaneous coronary intervention; and
EMI, ST-elevation myocardial infarction.
*Although individual circumstances will vary, clinical stability is defined by
e absence of low output, hypotension, persistent tachycardia, apparent
ock, high-grade ventricular or symptomatic supraventricular tachyarrhyth-
ias, and spontaneous recurrent ischemia.s recurrent ischemia.
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ospital Discharge
ASS I
PCI is indicated in a noninfarct artery at a time separate from
primary PCI in patients who have spontaneous symptoms of
myocardial ischemia. (Level of Evidence: C)
ASS IIa
PCI is reasonable in a noninfarct artery at a time separate from
primary PCI in patients with intermediate- or high-risk findings on
noninvasive testing (58,141,142). (Level of Evidence: B)
.4. Adjunctive Antithrombotic Therapy to
upport Delayed PCI After Fibrinolytic
herapy
ee Table 9 for a summary of recommendations from this
ble 9. Adjunctive Antithrombotic Therapy to Support PCI After
tiplatelet Therapy
pirin
● 162- to 325-mg loading dose given with fibrinolytic agent (before PCI). Se
ction 4.2.1 and Table 5.
● 81- to 325-mg daily maintenance dose after PCI (indefinite)
● 81 mg daily is the preferred daily maintenance dose
Y12 receptor inhibitors
Loading doses
r patients who received a loading dose of clopidogrel with fibrinolytic therap
● Continue clopidogrel 75 mg daily without an additional loading dose
r patients who have not received a loading dose of clopidogrel:
● If PCI is performed 24 h after fibrinolytic therapy: clopidogrel 300-mg
loading dose before or at the time of PCI
● If PCI is performed 24 h after fibrinolytic therapy: clopidogrel 600-mg
loading dose before or at the time of PCI
● If PCI is performed 24 h after treatment with a fibrin-specific agent or
48 h after a non–fibrin-specific agent: prasugrel 60 mg at the time of P
r patients with prior stroke/TIA: prasugrel
Maintenance doses and duration of therapy
S placed: Continue therapy for at least 1 y with:
● Clopidogrel: 75 mg daily
● Prasugrel: 10 mg daily
S* placed: Continue therapy for at least 30 d and up to 1 y with:
● Clopidogrel: 75 mg daily
● Prasugrel: 10 mg daily
ticoagulant Therapy
● Continue UFH through PCI, administering additional IV boluses as needed t
maintain therapeutic ACT depending on use of GP IIb/IIIa receptor antagoni
● Continue enoxaparin through PCI:
● No additional drug if last dose was within previous 8 h
● 0.3-mg/kg IV bolus if last dose was 8 to 12 h earlier
● Fondaparinux:
● As sole anticoagulant for PCI
ACT indicates activated clotting time; BMS, bare-metal stent; COR, Class of Re
Evidence; N/A, not available; PCI, percutaneous coronary intervention; TIA, tr
*Balloon angioplasty without stent placement may be used in selected patien
dergoing balloon angioplasty after fibrinolysis alone according to the recomm
†The recommended ACT with no planned GP IIb/IIIa receptor antagonist treaction..4.1. Antiplatelet Therapy to Support PCI After
ibrinolytic Therapy
ASS I
After PCI, aspirin should be continued indefinitely (76,77,
80,82,121,122). (Level of Evidence: A)
Clopidogrel should be provided as follows:
a. A 300-mg loading dose should be given before or at the
time of PCI to patients who did not receive a previous
loading dose and who are undergoing PCI within 24 hours
of receiving fibrinolytic therapy (Level of Evidence: C);
b. A 600-mg loading dose should be given before or at the
time of PCI to patients who did not receive a previous
loading dose and who are undergoing PCI more than 24
hours after receiving fibrinolytic therapy (Level of Evi-
dence: C); and
c. A dose of 75 mg daily should be given after PCI (83,85,
olytic Therapy
COR LOE References
I A (113,121,122)
I A (76,77,80,82,121,122)
IIa B (76,82,86,87)
I C (83,85,121,122)
I C N/A
I C N/A
IIa B (83,85)
III: Harm B (83)
I C (83,85,121,122)
IIa B (83,85)
I C (121,122)
IIa B (83,85)
I C N/A
I B (127,149)
III: Harm C (110)
dation; DES, drug-eluting stent; GP, glycoprotein; IV, intravenous; LOE, Level
ischemic attack; and UFH, unfractionated heparin.
ght be reasonable to provide P2Y12 inhibitor therapy to patients with STEMI
ns listed for BMS. (Level of Evidence: C)
250–300 s (HemoTec device) or 300–350 s (Hemochron device).Fibrin
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After PCI, it is reasonable to use 81 mg of aspirin per day in
preference to higher maintenance doses (76,82,86,87). (Level
of Evidence: B)
Prasugrel, in a 60-mg loading dose, is reasonable once the
coronary anatomy is known in patients who did not receive a
previous loading dose of clopidogrel at the time of administra-
tion of a fibrinolytic agent, but prasugrel should not be given
sooner than 24 hours after administration of a fibrin-specific
agent or 48 hours after administration of a non–fibrin-specific
agent (83,85). (Level of Evidence: B)
Prasugrel, in a 10-mg daily maintenance dose, is reasonable
after PCI (83,85). (Level of Evidence: B)
ASS III: HARM
Prasugrel should not be administered to patients with a history
of prior stroke or transient ischemic attack (83). (Level of
Evidence: B)
.4.2. Anticoagulant Therapy to Support PCI After
ibrinolytic Therapy
ASS I
For patients with STEMI undergoing PCI after receiving fibrino-
lytic therapy with intravenous UFH, additional boluses of
intravenous UFH should be administered as needed to sup-
port the procedure, taking into account whether GP IIb/IIIa
receptor antagonists have been administered. (Level of
Evidence: C)
For patients with STEMI undergoing PCI after receiving fibrino-
lytic therapy with enoxaparin, if the last subcutaneous dose
was administered within the prior 8 hours, no additional
enoxaparin should be given; if the last subcutaneous dose
was administered between 8 and 12 hours earlier, enoxa-
parin 0.3 mg/kg IV should be given (127,149). (Level of
Evidence: B)
ASS III: HARM
Fondaparinux should not be used as the sole anticoagulant to
support PCI. An additional anticoagulant with anti-IIa activ-
ity should be administered because of the risk of catheter
thrombosis (110). (Level of Evidence: C)
. Coronary Artery Bypass Graft Surgery:
ecommendations
.1. CABG in Patients With STEMI
ASS I
Urgent CABG is indicated in patients with STEMI and coronary
anatomy not amenable to PCI who have ongoing or recurrent
ischemia, cardiogenic shock, severe HF, or other high-risk
features (150–152). (Level of Evidence: B)
CABG is recommended in patients with STEMI at time of
operative repair of mechanical defects (153–157). (Level of
Evidence: B)
ASS IIa
The use of mechanical circulatory support is reasonable in
patients with STEMI who are hemodynamically unstable and
require urgent CABG. (Level of Evidence: C) anASS IIb
Emergency CABG within 6 hours of symptom onset may be
considered in patients with STEMI who do not have cardiogenic
shock and are not candidates for PCI or fibrinolytic therapy.
(Level of Evidence: C)
.2. Timing of Urgent CABG in Patients With
TEMI in Relation to Use of Antiplatelet
gents
ASS I
Aspirin should not be withheld before urgent CABG (158).
(Level of Evidence: C)
Clopidogrel or ticagrelor should be discontinued at least 24
hours before urgent on-pump CABG, if possible (159–163).
(Level of Evidence: B)
Short-acting intravenous GP IIb/IIIa receptor antagonists (ep-
tifibatide, tirofiban) should be discontinued at least 2 to 4
hours before urgent CABG (164,165). (Level of Evidence: B)
Abciximab should be discontinued at least 12 hours before
urgent CABG (137). (Level of Evidence: B)
ASS IIb
Urgent off-pump CABG within 24 hours of clopidogrel or ticagre-
lor administration might be considered, especially if the bene-
fits of prompt revascularization outweigh the risks of bleeding
(160,166–168). (Level of Evidence: B)
Urgent CABG within 5 days of clopidogrel or ticagrelor admin-
istration or within 7 days of prasugrel administration might be
considered, especially if the benefits of prompt revasculariza-
tion outweigh the risks of bleeding. (Level of Evidence: C)
. Routine Medical Therapies:
ecommendations
.1. Beta Blockers
ASS I
Oral beta blockers should be initiated in the first 24 hours in
patients with STEMI who do not have any of the following:
signs of HF, evidence of a low-output state, increased risk for
cardiogenic shock, or other contraindications to use of oral
beta blockers (PR interval more than 0.24 seconds, second- or
third-degree heart block, active asthma, or reactive airways
disease) (169–171). (Level of Evidence: B)
Beta blockers should be continued during and after hospital-
ization for all patients with STEMI and with no contraindica-
tions to their use (172,173). (Level of Evidence: B)
Patients with initial contraindications to the use of beta blockers in
the first 24 hours after STEMI should be reevaluated to determine
their subsequent eligibility. (Level of Evidence: C)
ASS IIa
It is reasonable to administer intravenous beta blockers at the
time of presentation to patients with STEMI and no contrain-
isk factors for cardiogenic shock (the greater the number of risk factors present,
e higher the risk of developing cardiogenic shock) are age 70 years, systolic
ood pressure 120 mm Hg, sinus tachycardia 110 bpm or heart rate 60 bpm,
d increased time since onset of symptoms of STEMI.
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ischemia (169–171). (Level of Evidence: B)
.2. Renin-Angiotensin-Aldosterone System
hibitors
ASS I
An angiotensin-converting enzyme inhibitor should be admin-
istered within the first 24 hours to all patients with STEMI
with anterior location, HF, or ejection fraction less than or
equal to 0.40, unless contraindicated (174–177). (Level of
Evidence: A)
An angiotensin receptor blocker should be given to patients
with STEMI who have indications for but are intolerant of
angiotensin-converting enzyme inhibitors (178,179). (Level of
Evidence: B)
An aldosterone antagonist should be given to patients with
STEMI and no contraindications who are already receiving an
angiotensin-converting enzyme inhibitor and beta blocker
and who have an ejection fraction less than or equal to 0.40
and either symptomatic HF or diabetes mellitus (180).
(Level of Evidence: B)
ASS IIa
Angiotensin-converting enzyme inhibitors are reasonable for all
patients with STEMI and no contraindications to their use
(181–183). (Level of Evidence: A)
.3. Lipid Management
ASS I
High-intensity statin therapy should be initiated or continued in
all patients with STEMI and no contraindications to its use
(184,188,189). (Level of Evidence: B)
ASS IIa
It is reasonable to obtain a fasting lipid profile in patients with
STEMI, preferably within 24 hours of presentation. (Level of
Evidence: C)
. Complications After STEMI:
ecommendations
.1. Treatment of Cardiogenic Shock
ASS I
Emergency revascularization with either PCI or CABG is rec-
ommended in suitable patients with cardiogenic shock due to
pump failure after STEMI irrespective of the time delay from MI
onset (54,190,191). (Level of Evidence: B)
In the absence of contraindications, fibrinolytic therapy should
be administered to patients with STEMI and cardiogenic shock
who are unsuitable candidates for either PCI or CABG
(16,192,193). (Level of Evidence: B)
ASS IIa
The use of intra-aortic balloon pump counterpulsation can be
useful for patients with cardiogenic shock after STEMI who do
not quickly stabilize with pharmacological therapy (194–
197,197a). (Level of Evidence: B) mASS IIa
Alternative left ventricular (LV) assist devices for circulatory
support may be considered in patients with refractory cardio-
genic shock. (Level of Evidence: C)
.2. Implantable Cardioverter-Defibrillator
herapy Before Discharge
ASS I
Implantable cardioverter-defibrillator therapy is indicated be-
fore discharge in patients who develop sustained ventricular
tachycardia/ventricular fibrillation more than 48 hours after
STEMI, provided the arrhythmia is not due to transient or
reversible ischemia, reinfarction, or metabolic abnormalities
(198–200). (Level of Evidence: B)
.3. Pacing in STEMI
ASS I
Temporary pacing is indicated for symptomatic bradyarrhyth-
mias unresponsive to medical treatment. (Level of Evidence: C)
.4. Management of Pericarditis After STEMI
ASS I
Aspirin is recommended for treatment of pericarditis after
STEMI (201). (Level of Evidence: B)
ASS IIa
Administration of acetaminophen, colchicine, or narcotic anal-
gesics may be reasonable if aspirin, even in higher doses, is not
effective. (Level of Evidence: C)
ASS III: HARM
Glucocorticoids and nonsteroidal antiinflammatory drugs are
potentially harmful for treatment of pericarditis after STEMI
(202,203). (Level of Evidence: B)
.5. Anticoagulation¶
ASS I
Anticoagulant therapy with a vitamin K antagonist should be
provided to patients with STEMI and atrial fibrillation with
CHADS2# score greater than or equal to 2, mechanical heart
valves, venous thromboembolism, or hypercoagulable disorder.
(Level of Evidence: C)
The duration of triple-antithrombotic therapy with a vitamin K
antagonist, aspirin, and a P2Y12 receptor inhibitor should be
hese recommendations apply to patients who receive intracoronary stents during
I for STEMI. Among individuals with STEMI who do not receive an
tracoronary stent, the duration of DAPT beyond 14 days has not been studied
equately for patients who undergo balloon angioplasty alone, are treated with
rinolysis alone, or do not receive reperfusion therapy. In this subset of patients
th STEMI who do not receive an intracoronary stent, the threshold for initiation
oral anticoagulation for secondary prevention, either alone or in combination
th aspirin, may be lower, especially if a shorter duration (i.e., 14 days) of DAPT
planned (204).
#CHADS2 (Congestive heart failure, Hypertension, Age 75 years, Diabetes
ellitus, previous Stroke/transient ischemic attack [doubled risk weight]) score.
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(Level of Evidence: C)
ASS IIa
Anticoagulant therapy with a vitamin K antagonist is reason-
able for patients with STEMI and asymptomatic LV mural
thrombi. (Level of Evidence: C)
ASS IIa
Anticoagulant therapy may be considered for patients with
STEMI and anterior apical akinesis or dyskinesis. (Level of
Evidence: C)
Targeting vitamin K antagonist therapy to a lower international
normalized ratio (e.g., 2.0 to 2.5) might be considered in
patients with STEMI who are receiving DAPT. (Level of Evi-
dence: C)
. Risk Assessment After STEMI:
ecommendations
.1. Use of Noninvasive Testing for Ischemia
efore Discharge
ASS I
Noninvasive testing for ischemia should be performed before
discharge to assess the presence and extent of inducible
ischemia in patients with STEMI who have not had coronary
angiography and do not have high-risk clinical features for
which coronary angiography would be warranted (209–211).
(Level of Evidence: B)
ASS IIa
Noninvasive testing for ischemia might be considered before
discharge to evaluate the functional significance of a nonin-
farct artery stenosis previously identified at angiography.
(Level of Evidence: C)
Noninvasive testing for ischemia might be considered before
discharge to guide the postdischarge exercise prescription.
(Level of Evidence: C)
.2. Assessment of LV Function
ASS I
LV ejection fraction should be measured in all patients with
STEMI. (Level of Evidence: C)
.3. Assessment of Risk for Sudden Cardiac
eath
ASS I
Patients with an initially reduced LV ejection fraction who are
possible candidates for implantable cardioverter-defibrillator
therapy should undergo reevaluation of LV ejection fraction 40
or more days after discharge (212–215). (Level of Evidence: B)
ndividual circumstances will vary and depend on the indications for triple therapy
d the type of stent placed during PCI. After this initial treatment period, consider
erapy with a vitamin K antagonist plus a single antiplatelet agent. For patients
ated with fibrinolysis, consider triple therapy for 14 days, followed by a vitamin
antagonist plus a single antiplatelet agent (205–208).0. Posthospitalization Plan of Care:
ecommendations
ASS I
Posthospital systems of care designed to prevent hospital
readmissions should be used to facilitate the transition to
effective, coordinated outpatient care for all patients with
STEMI (216–220). (Level of Evidence: B)
Exercise-based cardiac rehabilitation/secondary prevention pro-
grams are recommended for patients with STEMI (221–224).
(Level of Evidence: B)
A clear, detailed, and evidence-based plan of care that pro-
motes medication adherence, timely follow-up with the health-
care team, appropriate dietary and physical activities, and
compliance with interventions for secondary prevention should
be provided to patients with STEMI. (Level of Evidence: C)
Encouragement and advice to stop smoking and to avoid
secondhand smoke should be provided to patients with STEMI
(225–228). (Level of Evidence: A)79,185–187
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